Cargando…

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges

BACKGROUND: Biliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). METHODS &...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizzo, Alessandro, Federico, Alessandro Di, Ricci, Angela Dalia, Frega, Giorgio, Palloni, Andrea, Pagani, Rachele, Tavolari, Simona, Marco, Mariacristina Di, Brandi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642057/ https://www.ncbi.nlm.nih.gov/pubmed/33356500 http://dx.doi.org/10.1177/1073274820983013

Ejemplares similares

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
por: Palloni, Andrea, et al.
Publicado: (2023)

Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
por: Brandi, Giovanni, et al.
Publicado: (2012)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
por: Frega, Giorgio, et al.
Publicado: (2020)

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
por: Rizzo, Alessandro, et al.
Publicado: (2022)

IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
por: Brandi, Giovanni, et al.
Publicado: (2022)

In Reply
por: Brandi, Giovanni, et al.
Publicado: (2016)

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma
por: Deiana, Chiara, et al.
Publicado: (2023)

Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
por: Vasuri, Francesco, et al.
Publicado: (2023)

Bile cell‑free DNA: a game changer for management of biliary tract cancer?
por: Rizzo, A., et al.
Publicado: (2022)

Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster
por: Brandi, Giovanni, et al.
Publicado: (2020)

Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective
por: Fratta, Elisabetta, et al.
Publicado: (2023)

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
por: Di Marco, Mariacristina, et al.
Publicado: (2020)

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
por: De Lorenzo, Stefania, et al.
Publicado: (2018)

Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
por: Carloni, Riccardo, et al.
Publicado: (2022)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review
por: Tavolari, Simona, et al.
Publicado: (2023)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
por: Frega, Giorgio, et al.
Publicado: (2023)

Two Case Reports of Biliary Tract Injuries during Laparoscopic Cholecystectomy
por: Romano, O., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_n419lii65ho2uac0ptnr2pbj09